Rivastigmine and Urinary retention - a phase IV clinical study of FDA data

Summary:

Urinary retention is reported as a side effect among people who take Rivastigmine (rivastigmine tartrate), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lyrica, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Urinary retention when taking Rivastigmine. It is created by eHealthMe based on reports of 7,475 people who have side effects when taking Rivastigmine from the FDA, and is updated regularly.

What is Rivastigmine?

Rivastigmine has active ingredients of rivastigmine tartrate. It is often used in dementia. eHealthMe is studying from 7,517 Rivastigmine users. Check the latest studies of Rivastigmine.

What is Urinary retention?

Urinary retention (the inability to completely or partially empty the bladder) is found to be associated with 1,567 drugs and 1,741 conditions by eHealthMe. Check the latest studies of Urinary retention.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

7,475 people reported to have side effects when taking Rivastigmine.
Among them, 71 people (0.95%) have Urinary retention.

Could Rivastigmine cause Urinary retention?

Among these 71 people:

How long have people been on Rivastigmine when they have Urinary retention? *

What is the gender of people who have Urinary retention when taking Rivastigmine? *

female: 40.91 %
male: 59.09 %

What is the age of people who have Urinary retention when taking Rivastigmine? *

What are other drugs people take besides Rivastigmine? *

What are other side effects people have besides Urinary retention? *

Weakness: 13 people, 18.31%
Abdominal Distension: 12 people, 16.90%
Nausea (feeling of having an urge to vomit): 12 people, 16.90%
Fall: 11 people, 15.49%
Abdominal Pain: 11 people, 15.49%
Drowsiness: 10 people, 14.08%
Swallowing Difficulty: 10 people, 14.08%
Diarrhea: 9 people, 12.68%
Intestinal Obstruction: 8 people, 11.27%
Constipation: 8 people, 11.27%

What are the existing conditions these people have? *

Parkinson's Disease: 26 people, 36.62%
Pain: 21 people, 29.58%
Hypersensitivity: 16 people, 22.54%
High Blood Pressure: 16 people, 22.54%
Diabetes: 14 people, 19.72%
Hallucinations (sensations that appear real but are created by your mind): 11 people, 15.49%
Delusion (a false belief or opinion): 7 people, 9.86%
Dementia With Lewy Bodies (progressive degenerative disease or syndrome of the brain): 6 people, 8.45%
High Blood Cholesterol: 4 people, 5.63%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 4 people, 5.63%

* Approximation only. Some reports may have incomplete information.

Do you take Rivastigmine and have Urinary retention?

- Check whether Urinary retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rivastigmine:

Rivastigmine (7,517 reports)

Browse all side effects of Rivastigmine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary retention:

Urinary retention (1,567 drugs)

Browse all the conditions that are associated with Urinary retention:

Urinary retention (1,741 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on rivastigmine tartrate (the active ingredients of Rivastigmine) and Rivastigmine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.